GLP1R and diabetes mellitus: Moreover, the results of the large liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial and other studies strengthened the very idea that the use of liraglutide (a GLP-1 agonist) was associated with a significant decrease in cardiovascular mortality compared to placebo [22].